USNA auf dem Weg zu 500% dieses Jahr.
mitliest, der weiss auch das Prof. Dr Jürgen Drews nicht nur Vorstand von GPC Biotech, Morphosys, Protein Design, Humane Genome ist, sondern auch Aufsichtsratsvorsitzender von Genaissance Pharmaceuticals in New Haven. Nur die kennt halt niemand hier zu Lande.
Gruss E.
Schaue jetzt heute-journal, tschüss für heute.
24.01.2003 1,41 1,44 1,25 1,40 110.800
23.01.2003 1,33 1,37 1,31 1,31 42.000
22.01.2003 1,30 1,39 1,30 1,34 33.000
21.01.2003 1,26 1,47 1,25 1,40 173.000
20.01.2003 1,25 1,25 1,20 1,21 32.900
17.01.2003 1,21 1,21 1,20 1,21 32.900
16.01.2003 1,25 1,29 1,21 1,25 63.233
15.01.2003 1,22 1,25 1,20 1,20 7.900
14.01.2003 1,25 1,26 1,20 1,20 12.897
13.01.2003 1,20 1,25 1,18 1,25 26.803
10.01.2003 1,14 1,25 1,00 1,19 38.036
09.01.2003 1,06 1,18 1,06 1,18 49.600
08.01.2003 1,05 1,11 1,05 1,09 154.100
07.01.2003 1,08 1,27 0,87 1,04 260.229
06.01.2003 0,80 0,92 0,80 0,87 17.650
03.01.2003 0,90 0,90 0,81 0,87 23.800
02.01.2003 0,88 0,93 0,86 0,88 22.100
01.01.2003 0,84 0,94 0,83 0,87 101.784
31.12.2002 0,84 0,94 0,83 0,87 101.784
Bin gerade intensiv an der Aufarbeitung der vergangenen Woche, wo ich im Skiurlaub war. Ist einiges zu tun...
Aber durch USA/Irak gibt es in diesen Tagen einiges zu Schleuderpreisen (passt ja zum Start des WSV..)
Bis morgen
Pavian
Und jetzt?...... Will ich fünf grüne Punkte, sonst verrat ich Euch nix mehr.
Gruss E.
Gewinn +220% auf USD 3.6 Mio. oder 34 Cents
EPS für 2003 auf USD 1.40 angehoben ---> KGV 17!
Und die gab es vor einem Jahr noch für 1 Dollar... tz tz tz...
52-weeks low bei 0,18, akt bei 3,63
EVOLVING SYSTEMS INC - Nasdaq SmallCap Market: EVOL
Consolidated Real-time Market Quote*
| Last | Change (%) | After Hours Chg (%)** | Bid | Ask | Trade Time |
| -- | -- |  0.279 (7.69) | 0 (0) | 0 (0) | -- |
Exchange Quote
| Last | Change (%) | Bid (size) | Ask (size) | Trade Time |
| 3.63 | 0.23 (6.76) | 0.01 (1) | 4.76 (20) | 15:59 |
| Day Volume | Last Size | Open | High | Low |
| 0 | 100 | 3.55 | 3.72 | 3.40 |
| Latest Ticks | # of Trades | Avg Trade Size | 52 Wk High | 52 Wk Low |
| --== | 271 | 0 | 3.65 | 0.18 |
| Prev Close | Avg Day Vol | |||
| 3.40 | 182,900 |
Gruss E.
Grüße Pavian
Wie bist Du aus USNA aufmerksam geworden? Woher beziehst Du Deine Infos?
Gruß
Kalle
Überwiegend arbeiten wir (schau mal in den US-Depotwettbewerb hier im Board) viel mit dem Internet. Da steckt richtig Arbeit dahinter, News suchen, Zahlen bewerten, Charts analysieren...
Hoffe ich konnte Dir ein wenig weiterhelfen.
Beste Grüße
Pavian
Legen nachbörslich über 2$ zu.
Bis zum Wochenende, zur Tradingrunde.
Gruss E.
| GENAISSANCE PHARMA INC |  |
| You can't navigate in the Quotes & Research area without a Javascript-enabled browser. | ||||||
| Enter symbol(s): Don't know the symbol? - 0){tmp+=sym.substring(0,x)+s; sym=sym.substring(x+1)}; return tmp+sym}; var tickers=document.symbol_entry.p.value; tickers=subst(tickers,'+','%2B'); tickers=subst(tickers,' ','%20'); tickers=subst(tickers,',','%2C'); location.href='/investments/portfolio/AddToPort/?AddToPortfolio=1&p='+tickers+'&ref=quotes&channel=investments'}">Add to your watchlist - Printer-friendly version |
| |||||
| GNSC |
| Last Trade | 2.48 | Volume | 248,725 | |||
| Change | +0.38 | Avg Volume | 121,496 | |||
| Bid / Ask | 2.32 / 2.40 | Mkt Cap (mil) | $57.14 | |||
| Open | 2.11 | P/E | N/E* | |||
| Prev Close | 2.10 | Div Yield | N/A | |||
| Day's Range | 2.07 - 2.50 | Annual Div/Sh | None | |||
| 52-wk Range | 0.37 - 2.26 | Market | NASDAQ | |||
| ||||||
| *N/E - No Earnings |
| Thursday, October 02, 2003 03:58 PM EDT. Quote delayed: 15 minutes Nasdaq, 20 minutes others. |
| Recent Headlines |
(Adds details, outlook, stock activity)
PALO ALTO, Calif., Oct 14 (Reuters) - USANA Health Sciences Inc. on Tuesday posted higher third-quarter earnings, raised its forecast for the fourth quarter and announced a stock split.
The company Salt Lake City-based maker of nutritional, personal care and weight management products, said its board approved a 2-for-1 stock split.
USANA shares, which had closed at $54.74 on the Nasdaq, were up 4 percent to $57 in extended trade on Instinet.
For its fiscal third quarter ended Sept. 27, USANA said net earnings rose to $6.1 million, or 57 cents per diluted share, from $2.3 million, or 22 cents per diluted share in the year ago period. Net sales grew to $52.5 million from $34.8 million a year ago.
The company attributed the increase in earnings to positive exchange rates and the opening of the South Korean market.
USANA said it bumped up guidance based on the third-quarter's results, forecasting fourth-quarter net sales approaching $57 million and earnings in the range of 57 cents to 59 cents a share, on a pre-split basis.
For 2004, USANA forecast sales of $240 million to $250 million and earnings of $2.45 per share to $2.55 per share, on a pre-split basis.
The company said the stock split will be effected by means of a stock dividend and will double the number of outstanding shares to about 19,050,000. Dividend shares will be distributed on or about Oct. 30, to stockholders of record as of Oct. 24, 2003.
((Reporting by Lisa Baertlein; Reuters Messaging: lisa.baertlein.reuters.com@reuters.net; 650-461-3401; Editing by Carol Bishopric))
For Related News, Double Click on one of these codes:
[E] [U] [RNP] [DNP] [PCO] [CRD] [PCU] [DRU] [US] [ISU] [RES] [RESF] [LEN] [RTRS] [USNA.O]
For Relevant Price Information, Double Click on one of these codes:
Tuesday, 14 October 2003 23:28:24
RTRS [nN14183872] {EN}
ENDS
Gruss E.
Genaissance Pharmaceuticals Secures $11.1 Million in Funding - Financing Package Could Total $15.4 Million -
NEW HAVEN, Conn., Oct 30, 2003 /PRNewswire-FirstCall via COMTEX/ -- Genaissance
Pharmaceuticals, Inc. (Nasdaq: GNSC) today announced that it has secured $11.1
million from two transactions with a potential for an additional investment of
$4.3 million.
RAM Trading, Ltd. ("RAM"), an affiliate of an existing investor, purchased
270,000 shares of newly-designated Series A Preferred Stock at a price of $22.50
per share, totaling approximately $6.1 million. The proceeds from the
transaction will be used for working capital and general corporate purposes.
These shares can be converted by RAM at any time into 2.7 million shares of
common stock. The preferred stock pays an annual cash dividend of 2%.
Genaissance also issued a warrant to RAM exercisable for an additional 190,000
shares of Series A Preferred Stock under the same terms until December 31, 2005.
If Genaissance's common stock price is above $4.00 for 23 consecutive business
days, RAM would be required to purchase the additional shares at a specified
time. If Genaissance sells the additional 190,000 shares, RAM's investment would
total approximately $10.4 million. In addition, Genaissance granted RAM certain
other rights, including registration rights and certain put rights that can be
exercised beginning on the third anniversary of the closing of the transaction.
Genaissance also announced that on September 30, 2003, it signed a three-year,
$5.0 million term loan with Comerica Bank. The funds from this loan were
primarily used to help repay all existing capital leases, substantially reducing
Genaissance's annual principal and interest payments.
"This funding completes the restructuring plan for our balance sheet, which we
began last year, and further helps position us financially to execute our
business plan of building the preeminent Pharmacogenetics company," said Kevin
Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "We
are extremely pleased by the additional support from an affiliate of one of our
significant shareholders, which we believe is a tangible expression of
confidence in our business."
Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of
human gene variation for the development of a new generation of DNA-based
diagnostic and therapeutic products. Genaissance markets its technology,
clinical development skills and pharmacogenetic services to the pharmaceutical
industry as a complete solution for improving the development, marketing and
prescribing of drugs. Genaissance has agreements with major pharmaceutical,
diagnostic and biotechnology companies. Genaissance is headquartered in Science
Park in New Haven, Connecticut. Visit the company's website at
www.genaissance.com.
This press release contains forward-looking statements, including statements
about the receipt of additional proceeds from the sale of Series A Preferred
Stock and our expected financial position. Such statements are subject to
certain factors, risks and uncertainties that may cause actual results, events
and performance to differ materially from those referred to in such statements,
including, but not limited to, the trading price of our common stock, our
expected cash proceeds, the attraction of new business and strategic partners,
the adoption of our technologies by the pharmaceutical industry, the timing and
success of clinical trials, competition from pharmaceutical, biotechnology and
diagnostics companies, the strength of our intellectual property rights, and
those risks identified in our Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on August 14, 2003, and in other filings we
make with the Securities and Exchange Commission from time to time. The
forward-looking statements contained herein represent the judgment of
Genaissance as of the date of this release. Genaissance disclaims any obligation
to update any forward-looking statement.
SOURCE Genaissance Pharmaceuticals, Inc.